Compare DVAX & PLSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DVAX | PLSE |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2004 | 2016 |
| Metric | DVAX | PLSE |
|---|---|---|
| Price | $15.39 | $14.45 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $26.50 | $22.00 |
| AVG Volume (30 Days) | ★ 3.3M | 180.7K |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $330,514,000.00 | $86,000.00 |
| Revenue This Year | $24.63 | N/A |
| Revenue Next Year | $15.85 | $1,002.94 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 26.73 | N/A |
| 52 Week Low | $9.20 | $12.56 |
| 52 Week High | $15.49 | $25.00 |
| Indicator | DVAX | PLSE |
|---|---|---|
| Relative Strength Index (RSI) | 89.00 | 49.88 |
| Support Level | $10.78 | $14.33 |
| Resistance Level | $15.49 | $15.96 |
| Average True Range (ATR) | 0.22 | 0.71 |
| MACD | 0.44 | 0.18 |
| Stochastic Oscillator | 97.74 | 43.84 |
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.